Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for ANDA 062662

Expand all

TAZICEF (CEFTAZIDIME)
1GM/VIAL
Marketing Status: Prescription

Active Ingredient: CEFTAZIDIME
Proprietary Name: TAZICEF
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 1GM/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A062662
Product Number: 002
Approval Date: Mar 6, 1986
Applicant Holder Full Name: HOSPIRA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

TAZICEF (CEFTAZIDIME)
2GM/VIAL
Marketing Status: Prescription

Active Ingredient: CEFTAZIDIME
Proprietary Name: TAZICEF
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 2GM/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A062662
Product Number: 003
Approval Date: Mar 6, 1986
Applicant Holder Full Name: HOSPIRA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

TAZICEF (CEFTAZIDIME)
6GM/VIAL
Marketing Status: Prescription

Active Ingredient: CEFTAZIDIME
Proprietary Name: TAZICEF
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 6GM/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A062662
Product Number: 004
Approval Date: Mar 6, 1986
Applicant Holder Full Name: HOSPIRA INC
Marketing Status:  Prescription
Patent and Exclusivity Information

TAZICEF (CEFTAZIDIME)
500MG/VIAL
Marketing Status: Discontinued

Active Ingredient: CEFTAZIDIME
Proprietary Name: TAZICEF
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 500MG/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A062662
Product Number: 001
Approval Date: Mar 6, 1986
Applicant Holder Full Name: HOSPIRA INC
Marketing Status:  Discontinued
Patent and Exclusivity Information